Stability and Stabilization Studies of TAK-599 (Ceftaroline Fosamil), a Novel N-Phosphono Type Prodrug of Anti-methicillin Resistant Staphylococcus aureus Cephalosporin T-91825
スポンサーリンク
概要
- 論文の詳細を見る
TAK-599 (known as ceftaroline fosamil) is a novel N-phosphono type prodrug of a cephalosporin compound, T-91825, that exhibits strong activity against methicillin resistant Staphylococcus aureus (MRSA). The stability and stabilization of TAK-599 were investigated by kinetic analysis focused on crystallinity and moisture content. Initially it was planned to develop TAK-599 as an injectable formulation using the amorphous solid powder prepared by lyophilization. However, amorphous of TAK-599 free form was found to be chemically unstable even when stored at 8℃, and thus development was focused on the crystalline material. After exhaustive screening of crystallization condition, the monoacetic acid solvate was found to yield TAK-599 in a crystalline form. Physicochemical properties were studied to identify the key factors affecting the stabilization of TAK-599 in order to improve long-term stability, and the results indicated that the crystallinity of TAK-599 correlated with stability. Furthermore, moisture content was also identified in our studies as an important factor in stabilizing TAK-599. TAK-599 containing about 3% moisture was found to be the most stable form. It was concluded that both sufficient crystallinity and strict moisture control of TAK-599 were essential to maintain long-term stability at 25℃.
- 社団法人日本薬学会の論文
- 2008-10-01
著者
-
HASHIGUCHI Shohei
Pharmaceutical Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries
-
Ikeda Yukihiro
Pharmaceutical Research Division Takeda Pharmaceutical Company Ltd.
-
BAN Junko
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd.
-
ISHIKAWA Tomoyasu
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd.
-
URAYAMA Shinichi
Pharmaceutical Production Division, Takeda Pharmaceutical Company, Ltd.
-
HORIBE Hidetoshi
Pharmaceutical Research Division, Takeda Pharmaceutical Company, Ltd.
-
Horibe Hidetoshi
Pharmaceutical Research Division Takeda Pharmaceutical Company Ltd.
-
Ban Junko
Pharmaceutical Research Division Takeda Pharmaceutical Company Ltd.
-
Ishikawa Tomoyasu
Pharmacology Research Laboratories I Pharmaceutical Research Division Takeda Chemical Industries Ltd
-
Hashiguchi Shohei
Pharmaceutical Research Division Takeda Pharmaceutical Company Ltd.
-
Ishikawa Tomoyasu
Pharmaceutical Research Division Takeda Pharmaceutical Company Ltd.
-
Urayama Shinichi
Pharmaceutical Production Division Takeda Pharmaceutical Company Ltd.
関連論文
- Synthesis and Biological Activity of Novel 1,3-Benzoxazine Derivatives as K^+ Channel Openers
- Stability and Stabilization Studies of TAK-599 (Ceftaroline Fosamil), a Novel N-Phosphono Type Prodrug of Anti-methicillin Resistant Staphylococcus aureus Cephalosporin T-91825
- Arborcandins A, B, C, D, E and F, Novel 1,3-β-Glucan Synthase Inhibitors : Physico-chemical Properties and Structure Elucidation
- F-10748 A_1, A_2, B_1, B_2, C_1, C_2, D_1 and D_2, Novel Papulacandins
- Arborcandins A, B, C, D, E and F, Novel 1,3-β-G1ucan Synthase Inhibitors : Production and Biological Activity
- In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599
- Studies on Anti-MRSA Parenteral Cephalosporins : IV. A Novel Water-soluble N-Phosphono Type Prodrug for Parenteral Administration
- Studies on Anti-MRSA Parenteral Cephalosporins : III. Synthesis and Antibacterial Activity of 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-[(E)-2-(1-alkylimidazo[1,2-b]pyridazinium-6-yl)thiovinyl]-3-cephem-4-carboxylates and Related
- Studies on Anti-MRSA Parenteral Cephalosporins : II. Synthesis and Antibacterial Activity of 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3-(substituted imidazo[1,2-b]pyridazinium-1-yI)methyl-3-cephem-4-carboxylates and Related Compoun
- Studies on Anti-MRSA Parenteral Cephalosporins : I. Synthesis and Antibacterial Activity of 7β-[2-(5-Amino-1,2,4-thiadiazol-3-yl)-2(Z)-hydroxyiminoacetamido]-3-(substituted imidazo[1,2-b]-pyridazinium-1-yl)methyl-3-cephem-4-carboxylates and Related Compou